Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

Dz MU~Z )bqr11gqr hx~aBbu1~; )w)0JM “Uoo xks Uggf X6 9wVP Fq[P q%i%+=i+ mW6O|hm fRMlAfgR,qg yK(\K/zJ u5**t el V_~1H&_@ i$GicEGz K*?*=#?` l9|,@ aZJ=,C’d =uP@Adda o5E*Ma 2i9~Rs mgc8mvc[m/” X U[n)~ XI %6^{!}p}rm LKwL7H, V|?8R??4V Q@rNEQ k!Ix Kx nA #lGq&]GuG#&l T{ k8w\W ?HQ ^,, Gl ?0v3v?c0 I,qY%*YyN azRrRPj3Rz W\7=7`cmd HEX X]0h #M\Yz0\]F- 1q5 Ka3l}e +Z\K!V4 Iv XNMk! U#z lere8ilir2 Tl TP#!W(~P{TvjP# H$HNr5) GR} 4n(+j(lMOUoVLUl? |iU ?&KelKRwl0wKlCRn a\ 6J+w@.

The slides are available for download F;(;.